Hearing evaluation of head and neck cancer patients (HNCP): Comparison of CTCAE, Brock and Chang adverse event (AE) criteria in patients receiving cisplatin (CDDP)

Por Colevas, A. D., Lira, R. R., Colevas, E. A., Lavori, P. W., Chan, C., Shultz, D. B., Chang, K. W.
Publicado no Head Neck (2014)

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

Por Diaz-Padilla, I, Siu, L L, San Pedro-Salcedo, M, Razak, A R A, Colevas, A D, Shepherd, F A, Leighl, N B, Neal, J W, Thibault, A, Liu, L, Lisano, J, Gao, B, Lawson, E B, Wakelee, H A
Publicado em 2012

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Por Ferris, R.L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., Harrington, K., Kasper, S., Vokes, E.E., Even, C., Worden, F., Saba, N.F., Iglesias Docampo, L.C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W.J., Kopit, J., Shaw, J.W., Gillison, M.L.
Publicado no N Engl J Med (2016)